摘要
目的观察重组人血管内皮抑制素（恩度）治疗恶性胸腔积液的近期疗效,评价恩度局部应用的疗效、安全性及耐受性。方法将病例随机分为两组：A组（治疗组）18例,B组（对照组）14例。治疗组胸腔注入恩度30 mg＋0.9%氯化钠注射液40 m l;对照组胸腔注入顺铂40 mg＋0.9%氯化钠注射液60 m l,每周2次,共2-4次。结果 A组（治疗组）中CR 5例,PR 9例,ND 4例,有效率77.8%。B组（对照组）CR2例,PR5例,ND7例,有效率50%。A组副反应较轻。结论顺铂和恩度胸腔灌注治疗恶性胸腔积液,均能有效控制恶性胸腔积液,但恩度有效率高于顺铂组,而且副反应较轻。
Objective To observe the clinical efficacy of recombinant human endostatin（Endostar）for control malignant pleural effusion,evaluate the safety and tolerability of intracavitary infusion of Endostar.Methods Thirty-two malignant tumors patients were divided into two groups.A group（therapy group,18 cases）were treated with Endostar into thoracic cavity.B group（control group,14 cases）were treated with Cisplatin,twice a week,in 2-3 rounds.Results The efficacy of therpy group：5 cases of CR,9 cases of PR,4 cases of ND with 77.8%efficiency rate;and 50%for the B group（control group）（P〈0.05）.The drug-related toxicity：control group were a little more than therapy group.Conclusion Endostar intracavitary infusion to cure malignant pleural effusion is safe and useful,the efficacy and tolerability is superior to cisplatin intracavitary infusion.
出处
《中国实用医药》
2011年第5期32-33,共2页
China Practical Medicine
